E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
BASAL CELL CARCINOMA |
carcinoma basocellulare cutaneo |
|
E.1.1.1 | Medical condition in easily understood language |
SKIN CANCER |
TUMORE CUTANEO |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10004146 |
E.1.2 | Term | Basal cell carcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess anti-tumor activity of DAC-0060 + Tazarotene 0.1% gel topic combination in the treatment of superficial and nodular basal cell skin cancer
|
Valutare l’attività antitumorale della combinazione DAC-0060 + Tazarotene 0.1% gel topico nel trattamento del carcinoma basocellulare cutaneo superficiale e nodulare |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety profile after repeated administrations of DAC-0060 + Tazarotene 0.1% gel topic combination in patients treated at the recommended doses
|
Valutare il profilo di sicurezza di somministrazioni ripetute della combinazione DAC-0060 + Tazarotene 0.1% gel topico in pazienti trattati alla dose raccomandata |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• A primary histologically confirmed BCC. • Relapsing and/or not respondent BCC. • Patients aged >18 years. • Patients must have at least one unidimensionally measurable lesion between 1 and 3 cm. • Negative serum pregnancy test for females of childbearing potential within 14 days of starting treatment. • If of childbearing potential, agreement to use adequate contraceptive methods (e.g., oral contraceptives, condoms, or other adequate barrier controls, intrauterine contraceptive devices, or sterilization) beginning at the screening visit and continuing until 3 months following last treatment with study drug. • Willing to abstain from application of non-study topical medications to the skin, during the study, including prescription and over the counter preparations. • Evidence of a personally signed and dated Ethics Committee-approved Informed Consent indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the study. • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures. • Patients already planned to undergo excision of the area treated during the trial period. • Agreement from the patient to allow photographs of the selected lesion to be taken and used as part of the study data package.
|
• Un carcinoma basocellulare cutaneo confermato istologicamente • Pazienti con carcinoma basocellulare naive • Carcinoma basocellulare cutaneo recidivante e/o non rispondente • Pazienti di età > ai 18 anni • I pazienti devono avere almeno una lesione misurabile unidimensionalmente tra 1 e 3 cm • Test di gravidanza negativo in donne in età fertile entro 14 giorni dall’ inizio del trattamento • Se donne potenzialmente fertile, accordo all’utilizzo di adeguati metodi contraccettivi (contraccettivi orali, condoms, o altri adeguati controlli di barriera, strumenti contraccettivi intrauterine, o sterilizzazione) a partire dalla visita di screening e continuando fino ai 3 mesi successive l’ultimo trattamento in studio • Volontà ad astenersi dalla applicazione di medicamenti topici per la pelle non previsti dallo studio, durante lo studio, inclusi preparati prescrivibili e non. • Evidenza di un Consenso Informato approvato dal Comitato Etico firmato e datato che indichi che il paziente (o il suo rappresentante legale) sia stato informato di tutti gli aspetti pertinenti dello studio • Volontà di aderire al programma di visite previste, al trattamento programmato, ai tests di laboratorio e alle alter procedure di studio • Pazienti già programmati a subire una escissione dell’area trattata durante il periodo di studio • Accordo del paziente a permettere che le fotografie della lesione selezionata siano effettuate e usate come facente parte dei dati dello studio
|
|
E.4 | Principal exclusion criteria |
• Non melanoma skin cancer other than BCC. • Presence of active infections (e.g. requiring antibiotic therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study. • Presence of known metastases. • Known to have a second uncontrolled cancer of other primary origin within the last 5 years. • Known history of hypersensitivity to any of the ingredients of the study medication formulation. • Pregnancy or breast feeding. Female patient must agree to use effective contraception, or be surgically sterile or postmenopausal. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. • Participation to other studies or treatment with an investigational study drug in the last six months. • Any conditions that in the opinion of the investigator could hamper compliance with the study protocol. • Transplanted patients |
Tumore della pelle di tipo non melanoma diverso dal carcinoma basocellulare cutaneo • Presenza di infezioni attive (ex. richiedenti terapia antibiotica) o altra patologia concomitante che, secondo l’opinione dell’investigatore, potrebbe sottoporre il paziente ad un rischio ingiustificato o interferire con lo studio. • Presenza di metastasi note • Storia nota di un secondo tumore incontrollato di altra origine primaria negli ultimo 5 anni • Storia nota di ipersensibilità ad un qualunque componente del trattamento di studio • Gravidanza o allattamento. Pazienti di sesso femminile devono essere d’accordo ad utilizzare un contraccettivo efficace, o essere chirurgicamente sterile o in postmenopausa. La definizione di contraccettivo efficace si baserà sul giudizio del principal investigator o di un associate designato. • Partecipazione ad altri studi o trattamento con farmaco sperimentale negli ultimo sei mesi. • Qualunque condizione che a giudizio dello sperimentatore potrebbe ostacolare la compliance con il protocollo in studio • Pazienti trapiantati |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Evaluation of the composite response
|
Valutazione della risposta composita |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
9 weeks after the beginning of treatment |
9 settimane dall’ inizio del trattamento |
|
E.5.2 | Secondary end point(s) |
Evaluation of the objective response Evaluation of the overall response Toxicity
|
Valutazione della risposta obiettiva Valutazione della risposta complessiva Tossicità |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
9 weeks after the beginning of treatment |
9 settimane dall’ inizio del trattamento |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |